Literature DB >> 23518344

Interweaving the strands: β-catenin, an HIV co-receptor, and Schwann cell tumors.

David Largaespada1, Nancy Ratner.   

Abstract

WNT/β-catenin signaling is critical to the development of many cancer types. A paper by Mo and colleagues in a recent issue of Cell shows that autocrine CXCL12/CXCR4 chemokine signaling activates β-catenin signaling in a rare peripheral nerve sarcoma. Together with the availability of small molecules targeting CXCR4, this finding suggests new avenues for cancer therapy.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Year:  2013        PMID： 23518344      PMCID： PMC3635484          DOI： 10.1016/j.ccr.2013.03.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  Wnt/β-catenin signaling and disease.

Authors:  Hans Clevers; Roel Nusse
Journal:  Cell       Date:  2012-06-08       Impact factor: 41.582

Review 2.  Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Authors:  Brigitte C Widemann
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

3.  CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors.

Authors:  Wei Mo; Jian Chen; Amish Patel; Liang Zhang; Vincent Chau; Yanjiao Li; Woosung Cho; Kyun Lim; Jing Xu; Alexander J Lazar; Chad J Creighton; Svetlana Bolshakov; Renée M McKay; Dina Lev; Lu Q Le; Luis F Parada
Journal:  Cell       Date:  2013-02-21       Impact factor: 41.582

4.  Assessing the role of the cadherin/catenin complex at the Schwann cell-axon interface and in the initiation of myelination.

Authors:  Kathryn A Lewallen; Yun-An A Shen; Asia R De la Torre; Benjamin K Ng; Dies Meijer; Jonah R Chan
Journal:  J Neurosci       Date:  2011-02-23       Impact factor: 6.167

Review 5.  A review on CXCR4/CXCL12 axis in oncology: no place to hide.

Authors:  Urszula M Domanska; Roeliene C Kruizinga; Wouter B Nagengast; Hetty Timmer-Bosscha; Gerwin Huls; Elisabeth G E de Vries; Annemiek M E Walenkamp
Journal:  Eur J Cancer       Date:  2012-06-09       Impact factor: 9.162

6.  Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

Authors:  Thomas De Raedt; Zandra Walton; Jessica L Yecies; Danan Li; Yimei Chen; Clare F Malone; Ophélia Maertens; Seung Min Jeong; Roderick T Bronson; Valerie Lebleu; Raghu Kalluri; Emmanuel Normant; Marcia C Haigis; Brendan D Manning; Kwok-Kin Wong; Kay F Macleod; Karen Cichowski
Journal:  Cancer Cell       Date:  2011-09-13       Impact factor: 31.743

Review 7.  The way Wnt works: components and mechanism.

Authors:  Kenyi Saito-Diaz; Tony W Chen; Xiaoxi Wang; Curtis A Thorne; Heather A Wallace; Andrea Page-McCaw; Ethan Lee
Journal:  Growth Factors       Date:  2012-12-21       Impact factor: 2.511

8.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

9.  Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.

Authors:  Yan-Xi Sun; Jingcheng Wang; Charles E Shelburne; Dennis E Lopatin; Arul M Chinnaiyan; Mark A Rubin; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2003-06-01       Impact factor: 4.429

10.  Temporal control of neural crest lineage generation by Wnt/β-catenin signaling.

Authors:  Lisette Hari; Iris Miescher; Olga Shakhova; Ueli Suter; Lynda Chin; Makoto Taketo; William D Richardson; Nicoletta Kessaris; Lukas Sommer
Journal:  Development       Date:  2012-05-09       Impact factor: 6.868
  10 in total
  7 in total

Review 1.  Notch Signaling and the Skeleton.

Authors:  Stefano Zanotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2016-04-13       Impact factor: 19.871

Review 2.  Clinical and experimental aspects of notch receptor signaling: Hajdu-Cheney syndrome and related disorders.

Authors:  Ernesto Canalis
Journal:  Metabolism       Date:  2017-08-24       Impact factor: 8.694

3.  An antibody to Notch3 reverses the skeletal phenotype of lateral meningocele syndrome in male mice.

Authors:  Jungeun Yu; Christian W Siebel; Lauren Schilling; Ernesto Canalis
Journal:  J Cell Physiol       Date:  2019-06-12       Impact factor: 6.384

4.  The Hajdu Cheney Mutation Is a Determinant of B-Cell Allocation of the Splenic Marginal Zone.

Authors:  Jungeun Yu; Stefano Zanotti; Bhavita Walia; Evan Jellison; Archana Sanjay; Ernesto Canalis
Journal:  Am J Pathol       Date:  2017-10-14       Impact factor: 4.307

5.  An Antibody to Notch2 Reverses the Osteopenic Phenotype of Hajdu-Cheney Mutant Male Mice.

Authors:  Ernesto Canalis; Archana Sanjay; Jungeun Yu; Stefano Zanotti
Journal:  Endocrinology       Date:  2017-04-01       Impact factor: 4.736

6.  Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours.

Authors:  Laura E Thomas; Jincy Winston; Ellie Rad; Matthew Mort; Kayleigh M Dodd; Andrew R Tee; Fionnuala McDyer; Stephen Moore; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2015-02-15       Impact factor: 4.639

7.  WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth.

Authors:  Craig S Thomson; Jay Pundavela; Melissa R Perrino; Robert A Coover; Kwangmin Choi; Katherine E Chaney; Tilat A Rizvi; David A Largaespada; Nancy Ratner
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.